BioWorld

Aug. 31, 2006

Genzyme Wants AnorMed For $380M; AnorMed Uninterested

After AnorMed Inc.'s board rejected an unsolicited $380 million takeover bid, Genzyme Corp. said it plans to go to AnorMed shareholders with a proposal to acquire the company. (BioWorld Today) Read More

OrthoLogic's Stock Dips As Phase IIb Misses Endpoint

P38 MAP Kinase Block May Foil One More Autoimmune Disorder

Roche Returns Zenapax Rights In Asthma To PDL

Clinic Roundup

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for June 11, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for June 11, 2025.

AI-generated illustration of heart and metabolic impact

Deep Apple signs big Novo deal for cardiometabolic small molecules

BioWorld

Deep Apple Therapeutics Inc. could bring in as much as $812 million in a new collaboration and license deal with Novo Nordisk A/S. The total includes an...

DNA double helix under a magnifying glass

23andme genetic privacy concerns garner Congressional scrutiny

BioWorld MedTech

The bankruptcy of genetic testing service 23andme Holding Corp. prompted a reaction from many quarters, but a June 11 Senate hearing highlighted an interest in...

3Sbio revs on with phase II data in tight PD-1/VEGF bispecific race

BioWorld

3Sbio Inc. reported interim phase II study results of its PD-1/VEGF bispecific antibody, SSGJ-707 – a “fabulous” asset, according to Pfizer Inc. CEO Albert...